Citadel Advisors
NXTM

Citadel Advisors’s NxStage Medical Inc. NXTM Stock Holding History

Citadel Advisors’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,100
Closed -$633K – 10287
2018
Q4 		$633K Sell
22,100
-12,800
-37% -$364K ﹤0.01% 6039
2018
Q3 		$973K Buy
34,900
+21,000
+151% +$591K ﹤0.01% 5600
2018
Q2 		$388K Buy
13,900
+2,900
+26% +$77.8K ﹤0.01% 6787
2018
Q1 		$273K Buy
11,000
+2,000
+22% +$48.6K ﹤0.01% 6888
2017
Q4 		$218K Buy
+9,000
New +$237K ﹤0.01% 6987
2016
Q1 		– Sell
-2,500
Closed -$55K – 8622
2015
Q4 		$55K Sell
2,500
-3,700
-60% -$69K ﹤0.01% 7238
2015
Q3 		$98K Sell
6,200
-7,500
-55% -$120K ﹤0.01% 6975
2015
Q2 		$196K Buy
+13,700
New +$232K ﹤0.01% 6356
2015
Q1 		– Sell
-1,100
Closed -$20K – 9019
2014
Q4 		$20K Sell
1,100
-3,500
-76% -$56.4K ﹤0.01% 7816
2014
Q3 		$60K Buy
4,600
+3,600
+360% +$48.5K ﹤0.01% 6792
2014
Q2 		$14K Hold
1,000
– – ﹤0.01% 7473
2014
Q1 		$13K Buy
1,000
+700
+233% +$9.13K ﹤0.01% 7435
2013
Q4 		$3K Sell
300
-1,400
-82% -$15.9K ﹤0.01% 6880
2013
Q3 		$22K Buy
1,700
+1,600
+1,600% +$21K ﹤0.01% 6172
2013
Q2 		$1K Buy
+100
New +$1.26K ﹤0.01% 6448

Other funds holding NXTM

TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Citadel Advisors's NXTM Position: Q1 2019 in Review

Citadel Advisors sold out of NxStage Medical Inc. (NXTM) in Q1 2019, closing a stake of 1,662,607 shares — an estimated $47.6M sold.

Citadel Advisors first reported a position in NXTM in Q2 2013 and held it in 20 quarters. The position peaked at $47.6M in Q4 2018. 1 fund tracked by Wall St. Rank holds NXTM as of Q1 2019.

  • Citadel Advisors reported no remaining NxStage Medical Inc. position as of Q1 2019 after selling out during the quarter.
  • Citadel Advisors sold 1,662,607 NxStage Medical Inc. shares in Q1 2019, an estimated $47.6M.
  • Citadel Advisors first reported a position in NxStage Medical Inc. in Q2 2013 and held it in 20 quarters.
  • Citadel Advisors's NxStage Medical Inc. position peaked at $47.6M in Q4 2018.
  • 1 fund tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.